Hosted on MSN23d
MediWound announces Phase III CIDS publication on NexoBridThese results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...
Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne ...
These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...
These results reinforce NexoBrid's clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results